Is IRTC a Buy or a Sell? The Bull and Bear Case (2026)

That depends on which case you find more convincing, and both are on this page. The bull case rests on Zio volume growth and category leadership, with revenue (ttm) at ~$825M. The bear case rests on regulatory risk is material: iRhythm has been working through FDA warning-letter remediation, which raises compliance costs and can create clearance timing uncertainty for new products like Zio MCT. Analysts covering it are spread from $140.00 to $196.00, which is itself a signal that this is genuinely contested. If you believe the thesis, the real questions become sizing and overlap rather than timing. Walnut is not an investment adviser and this is not a recommendation.

Nobody can answer that for you, and the honest version of the question is narrower: has anything changed in the reason you bought it? The bear case on this page is the place to check. Regulatory risk is material: iRhythm has been working through FDA warning-letter remediation, which raises compliance costs and can create clearance timing uncertainty for new products like Zio MCT. If that risk is what you were worried about and it is now playing out, that is a real signal. If the price simply fell while the thesis held, that is a different situation entirely. The most pessimistic published target is $140.00, +28.8% from the $108.66 price, which is one analyst's downside case rather than a floor. Walnut is not an investment adviser.

Zio volume growth and category leadership. The core Zio service continues to take share from legacy Holter monitors, which have fallen from about 80% of the market to roughly 40% as long-term continuous monitoring becomes standard of care. The most optimistic analyst target on IRTC is $196.00, +80.4% from the $108.66 price. That figure is only reachable if this thesis works close to its best case.

Regulatory risk is material: iRhythm has been working through FDA warning-letter remediation, which raises compliance costs and can create clearance timing uncertainty for new products like Zio MCT. Reimbursement is the other central risk, since a large share of revenue depends on CMS and commercial payer rates that can be cut or restructured. Data security became a live issue in 2026: unauthorized individuals accessed and downloaded patient information (names, contact details, insurance numbers, dates of birth) from third-party-hosted business applications between June 3 and June 8, 2026, and iRhythm began notifying affected patients on October 2. The company says it does not expect a material financial impact and saw no effect on its devices or patient safety, but breaches can bring litigation and regulatory scrutiny. Integrating VitalConnect adds execution risk, and the balance sheet carries about $727 million of debt against about $591 million of cash. The company is still near GAAP break-even and trades at a premium revenue multiple, so any volume slowdown, pricing pressure or launch delay could compress the stock further, as its 37% drop in 2026 shows. Competition from larger, better-capitalized players (Philips, Boston Scientific) adds further risk, and medtech reimbursement and regulatory outcomes are difficult to predict. The most pessimistic published target is $140.00, +28.8% from the current price, which is roughly what the stock is worth if these risks bite rather than the drivers.

iRhythm Technologies makes the Zio service, a small adhesive patch that records a patient's heart rhythm continuously for up to 14 days and pairs it with AI-assisted analysis to de

Decide that in advance, because it is far harder to think clearly once a position is moving against you. The concrete tripwires here: the driver behind the bull case (Zio volume growth and category leadership) stalling in the reported numbers rather than in the narrative, the risk above (regulatory risk is material: iRhythm has been working through FDA warning-letter remediation, which raises compliance costs and can create clearance timing uncertainty for new products like Zio MCT) turning from a possibility into a reported fact, or the position growing large enough that a bad outcome would matter to your whole portfolio regardless of who is right.

iRhythm, now named iRhythm Holdings, makes the Zio service, an adhesive patch that continuously records a patient's heart rhythm for up to 14 days. The patch is mailed back and analyzed with AI-assisted algorithms to detect arrhythmias like atrial fibrillation, then a report is sent to the prescribing physician. Since October 2026 it also owns VitalConnect, which adds a 30-day mobile cardiac telemetry platform.

Not consistently on a GAAP basis. Trailing twelve-month net income is about -$14 million, though Q2 2026 came in at a loss of only about $0.4 million and Q4 2025 was profitable. The company is adjusted-EBITDA positive, has a positive operating margin of about 8%, and produced about $82 million of free cash flow over the last twelve months, so profitability is improving.

Trailing revenue is about $825 million, up from $747 million in fiscal 2025, and Q2 2026 revenue of about $224 million grew roughly 20% year over year. Analysts expect about $892 million for full-year 2026 and about $1.04 billion for 2027. Growth is driven by rising Zio prescription volumes and expanding payer coverage, and management expects VitalConnect to add to the growth rate from 2027.